Latest Media Releases

All  A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z 

CEO on IND status for VGX-100 (ASX:CIR)

15 Nov, 2011 10:20 AM

In this Open Briefing, CEO & MD Robert Klupacs discusses - Clinical and commercial implications of IND status for VGX-100 - Design, end points and time lines of Phase I trials - more

Van Leeuwenhoeck Research (ASX:CIR)

30 May, 2011 05:19 PM

Initiating Coverage Report 3.  Technology Circadian is developing a variety of drugs to block the interaction between VEGF Receptor-3 (VEGFR-3) and its ligands VEGF-C and VEGF-D. more

Viewing: 1 - 15 of 18  |